EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids



Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids



Journal of Virology 73(4): 3309-3316



Human immunodeficiency virus type 1 (HIV-1) and other retroviruses require integration of a double-stranded DNA copy of the RNA genome into the host cell chromosome for productive infection. The viral enzyme, integrase, catalyzes the integration of retroviral DNA and represents an attractive target for developing antiretroviral agents. We identified several derivatives of dicaffeoylquinic acids (DCQAs) that inhibit HIV-1 replication in tissue culture and catalytic activities of HIV-1 integrase in vitro. The specific step at which DCQAs inhibit the integration in vitro and the mechanism of inhibition were examined in the present study. Titration experiments with different concentrations of HIV-1 integrase or DNA substrate found that the effect of DCQAs was exerted on the enzyme and not the DNA. In addition to HIV-1, DCQAs also inhibited the in vitro activities of MLV integrase and truncated variants of feline immunodeficiency virus integrase, suggesting that these compounds interacted with the central core domain of integrase. The inhibition on retroviral integrases was relatively specific, and DCQAs had no effect on several other DNA-modifying enzymes and phosphoryl-transferases. Kinetic analysis and dialysis experiments showed that the inhibition of integrase by DCQAs was irreversible. The inhibition did not require the presence of a divalent cation and was unaffected by preassembling integrase onto viral DNA. The results suggest that the irreversible inhibition by DCQAs on integrase is directed toward conserved amino acid residues in the central core domain during catalysis.

(PDF emailed within 1 workday: $29.90)

Accession: 010885739

Download citation: RISBibTeXText

PMID: 10074185



Related references

Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrobial Agents and ChemoTherapy 42(1): 140-146, 1998

Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase. Molecular Pharmacology 50(4): 846-855, 1996

Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication. Journal of Medicinal Chemistry 42(3): 497-509, 1999

Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochemical Pharmacology. 49(8): 1165-1170, 1995

Inhibition of catalytic activities of HIV-1 integrase by dicaffeoylquinic acids. INFECTIOUS DISEASES SOCIETY OF AMERICA [Author], NATIONAL INSTITUTES OF HEALTH [Author], CENTERS FOR DISEASE CONTROL AND PREVENTION [Author] 3rd Conference on retroviruses and opportunistic infections : 178, 1996

Inhibition of human immunodeficiency virus type-1 integrase by 3-azido-2,3-dideoxythymidylate. FASEB Journal 8(7): A1468, 1994

Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Research 64(1): 35-45, 2004

Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate. Proceedings of the National Academy of Sciences of the United States of America 91(13): 5771-5775, 1994

Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 35(43): 13762-13771, 1996

Nucleic acids encoding a human immunodeficiency virus type 1 integrase interactor protein. Official Gazette of the United States Patent & Trademark Office Patents 1245(4), Apr 24, 2001

Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid. Antimicrobial Agents and ChemoTherapy 46(10): 3301-3303, 2002

Inhibition of human immunodeficiency virus type 1 integrase by a hydrophobic cation: The phenanthroline-cuprous complex. AIDS Research and Human Retroviruses 11(1): 115-125, 1995

Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proceedings of the National Academy of Sciences of the United States of America 92(19): 8818-8822, 1995

Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones. Antimicrobial Agents and ChemoTherapy 49(12): 4884-4894, 2005